Edition:
India

Baxter International Inc (BAX.N)

BAX.N on New York Stock Exchange

69.42USD
23 Jan 2018
Change (% chg)

$-0.78 (-1.11%)
Prev Close
$70.20
Open
$70.10
Day's High
$70.11
Day's Low
$69.40
Volume
145,820
Avg. Vol
715,359
52-wk High
$70.25
52-wk Low
$45.48

Latest Key Developments (Source: Significant Developments)

Baxter Announces U.S. FDA Approval Of Ready-To-Use Bivalirudin
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Baxter International Inc ::BAXTER ANNOUNCES U.S. FDA APPROVAL OF READY-TO-USE CARDIOVASCULAR MEDICATION BIVALIRUDIN.BAXTER INTERNATIONAL SAYS U.S. FDA APPROVED BIVALIRUDIN IN 0.9 PERCENT SODIUM CHLORIDE INJECTION.BAXTER INTERNATIONAL INC - BIVALIRUDIN IS EXPECTED TO LAUNCH IN UNITED STATES IN EARLY 2018.  Full Article

Mallinckrodt Will Sell Recothrom, Preveleak To Baxter for $185 Mln
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Mallinckrodt Plc :MALLINCKRODT WILL SELL RECOTHROM® AND PREVELEAK® TO BAXTER.MALLINCKRODT - TOTAL DEAL CONSIDERATION OF $185 MILLION, WITH $153 MILLION UPFRONT, INCLUDING EXISTING INVENTORY, REMAINDER IN POTENTIAL MILESTONE PAYMENTS.MALLINCKRODT PLC - WILL RETAIN RAPLIXA FOR TOPICAL USE AND IS EVALUATING STRATEGIC OPTIONS FOR THIS PRODUCT.MALLINCKRODT - ‍ SALE IS ANTICIPATED TO DILUTE CO'S ADJUSTED EARNINGS PER SHARE BY $0.10 TO $0.15 IN 2018, WHICH WILL BE OFFSET BY SHARES REPURCHASED DURING Q4 2017​.MALLINCKRODT PLC - COMPANY WILL DISCONTINUE MARKETING OF RAPLIXA UPON CLOSE OF BAXTER TRANSACTION.MALLINCKRODT PLC - PROCEEDS FROM SALE WILL BE USED BY COMPANY TOWARD PAYING DOWN DEBT.MALLINCKRODT PLC - ‍WRITE-OFF FOR RAPLIXA​ WILL BE REPORTED FOR Q4 2017.  Full Article

Baxter To Acquire Recothrom, Preveleak For Upfront Payment Of About $153 Mln
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Baxter International Inc ::BAXTER ANNOUNCES AGREEMENT TO BROADEN PORTFOLIO OF INNOVATIVE SURGICAL PRODUCTS.BAXTER INTERNATIONAL - TO ACQUIRE RECOTHROM AND PREVELEAK FOR UPFRONT PAYMENT OF ABOUT $153 MILLION AND POTENTIAL CONTINGENT PAYMENTS IN FUTURE.BAXTER INTERNATIONAL - UPON CLOSING, DEAL EXPECTED TO BE MODESTLY ACCRETIVE TO BAXTER'S 2018 ADJUSTED EPS & INCREASINGLY ACCRETIVE THEREAFTER.BAXTER INTERNATIONAL - ‍PROPOSED DEAL INCLUDES TWO HEMOSTAT & SEALANT PRODUCTS, INCLUDING STAND-ALONE RECOMBINANT THROMBIN, SURGICAL SEALANT​.  Full Article

Baxter sees Q4 revenue to be negatively impacted by about $70 mln due to temporary manufacturing disruptions resulting from Hurricane Maria​
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Baxter International Inc :Baxter reports third-quarter 2017 results and updates financial outlook for full-year 2017.Q3 GAAP earnings per share $0.45 from continuing operations.Q3 revenue $2.7 billion versus I/B/E/S view $2.66 billion.Q3 earnings per share view $0.59 -- Thomson Reuters I/B/E/S.Sees Q4 earnings per share $0.56 to $0.59 from continuing operations excluding items.Sees FY 2017 earnings per share $2.40 to $2.43 from continuing operations excluding items.Sees FY 2017 GAAP earnings per share $1.85 to $1.93.Baxter International Inc - ‍qtrly sales within U.S. were approximately $1.1 billion, advancing 8 percent​.Baxter International - Sees Q4 revenue to be negatively impacted by about $70 million due to temporary manufacturing disruptions resulting from Hurricane Maria​.Baxter - Qtrly ‍international sales about $1.6 billion, representing a 5 percent increase on reported basis and a 4 percent increase on a constant currency basis​.Baxter International - ‍For FY 2017, co now expects sales growth of about 4 percent on a reported basis, about 4 percent on a constant currency basis​.Q3 adjusted earnings per share $0.64 from continuing operations excluding items.Baxter International Inc - ‍Remains in limited production across all three manufacturing sites in Puerto Rico​.FY2017 earnings per share view $2.39, revenue view $10.50 billion -- Thomson Reuters I/B/E/S.  Full Article

Baxter provides update on Puerto Rico recovery status post Hurricane Maria
Friday, 13 Oct 2017 

Oct 12 (Reuters) - Baxter International Inc :Baxter provides update on Puerto Rico recovery status post Hurricane Maria.Baxter International Inc - ‍company expects to mitigate earnings impact from Hurricane Maria​.Baxter International Inc - ‍resumed limited production at all Puerto Rico manufacturing sites​.Baxter International Inc - ‍Baxter's three Puerto Rico manufacturing sites sustained minimal structural damage from impact of Hurricane Maria​.Baxter - co granted discretion for temporary importation of some products from facilities in Ireland, Australia to support product supply for U.S. market​.Baxter International Inc - ‍company does not manufacture large volume sterile solutions, such as its 1 liter IV solutions, in Puerto Rico​.  Full Article

Third Point Llc reports a stake of 7.5 pct in Baxter International
Saturday, 3 Jun 2017 

June 2 (Reuters) - Baxter International Inc :Third Point Llc reports a stake of 7.5 percent in Baxter International as of June 1 .Third Point Llc previously reported a stake of 8.5 percent in Baxter International as of Feb 28 .  Full Article

Baxter CEO José Almeida's FY 2016 compensation $5.8 mln vs $7.95 mln in FY 2015
Saturday, 18 Mar 2017 

Baxter International Inc :Ceo josé almeida's fy 2016 total compensation $5.8 million versus $7.95 million in fy 2015 - sec filing.  Full Article

Baxter Q3 adj earnings per share $0.56 from continuing operations excluding items
Tuesday, 25 Oct 2016 

Baxter International Inc : Baxter reports third quarter 2016 results and increases financial outlook for full-year 2016 . Sees Q4 2016 earnings per share $0.49 to $0.52 from continuing operations excluding items . Q3 GAAP earnings per share $0.23 from continuing operations . Q3 sales $2.6 billion versus i/b/e/s view $2.55 billion . Q3 earnings per share view $0.45 -- Thomson Reuters I/B/E/S . Raises FY 2016 earnings per share view to $1.88 to $1.91 from continuing operations excluding items . Q3 adjusted earnings per share $0.56 from continuing operations excluding items . Sees Q4 sales up about 2 percent . Baxter international inc - raising its financial outlook for full-year 2016 including sales growth of approximately 2 percent on a reported basis . Fy2016 earnings per share view $1.72, revenue view $10.15 billion -- Thomson Reuters I/B/E/S . Sees earnings from continuing operations, before special items, of $1.88 to $1.91 per diluted share for full year . Fy2016 earnings per share view $1.72 -- Thomson Reuters I/B/E/S . Baxter International Inc - on an adjusted basis Baxter's Q3 income from continuing operations totaled $0.56 per diluted share .Baxter International Inc - for Q4, company expects sales growth of approximately 2 percent on both a reported and constant currency basis.  Full Article

Sunshine Heart buys Baxter's Aquadex product line
Monday, 8 Aug 2016 

Sunshine Heart Inc: Sunshine Heart announces strategic acquisition of Aquadex product line from Baxter and a new credit facility with Silicon Valley Bank . Under terms of agreement, Baxter received $4.0 million in cash and 1.0 million shares of Sunshine Heart common stock . Entered into a new $5.0 million facility to finance future working capital needs . Company repaid all amounts outstanding under its existing debt facility with Silicon Valley Bank ."Expect product line to be accretive in first year".  Full Article

Baxter Q2 earnings $2.19/shr from cont ops
Tuesday, 26 Jul 2016 

Baxter Reports Second Quarter 2016 Results And Raises Financial Outlook For Full : Baxter reports second quarter 2016 results and raises financial outlook for full-year 2016 . For full-year 2016, baxter now expects sales growth of 3 percent to 4 percent on a constant currency basis . Year 2016 . Sees fy 2016 earnings per share $1.69 to $1.74 from continuing operations excluding items . Sees q3 2016 earnings per share $0.43 to $0.45 from continuing operations excluding items . Q2 gaap earnings per share $2.19 from continuing operations . Q2 sales $2.6 billion versus i/b/e/s view $2.52 billion . Q2 adjusted earnings per share $0.46 from continuing operations excluding items . Q2 earnings per share view $0.40 -- Thomson Reuters I/B/E/S . For full-year 2016, baxter now expects reported sales growth of 1 percent to 2 percent . Fy2016 earnings per share view $1.64, revenue view $10.09 billion -- Thomson Reuters I/B/E/S .Q3 earnings per share view $0.42, revenue view $2.53 billion -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Baxter Announces U.S. FDA Approval Of Ready-To-Use Bivalirudin

* BAXTER ANNOUNCES U.S. FDA APPROVAL OF READY-TO-USE CARDIOVASCULAR MEDICATION BIVALIRUDIN